Table 5.

Univariable and multivariable analysis of the effects of prognostic factors on recurrence-free survival and overall survival.

Chatacteristic	RFS				OS
	uni-HR (HR.95L-HR.95H)	pvalue	Multi-HR (HR.95L-HR.95H)	pvalue	HR (HR.95L-HR.95H)	pvalue
Regimens (pNCT vs TNT)	0.66 (0.38-0.99)	0.047	0.67 (0.41-1.10)	0.110	0.66 (0.43-3.60)	0.689
Sex (Female vs Male)	1.20 (0.63-2.12)	0.634	——	——	1.20 (0.45-26.14)	0.237
Age (Age<=65 vs Age>65)	0.65 (0.40-1.16)	0.155	——	——	0.65 (0.34-3.01)	0.991
cT_Stage (cT1&cT2&cT3 vs cT4)	1.30 (1.02-2.66)	0.04	1.30 (0.79-2.20)	0.300	1.30 (1.11-11.99)	0.033
cN_Stage (cN0 vs cN1&cN2)	1.00 (0.52-27.22)	0.187	——	——	1.00 (0-Inf)	0.998
MMR (unknown&pMMR vs dMMR)	1.50 (0.44-1.15)	0.165	——	——	1.50 (0.44-3.62)	0.665
CEA (CEA ≤ 5 vsCEA>5)	0.86 (0.87-2.56)	0.143	——	——	0.86 (0.04-2.47)	0.277
CRM (negative vs positive)	2.00 (0.96-2.95)	0.067	——	——	2.00 (0.50-6.49)	0.365
EMVI (negative vs positive)	2.20 (0.81-2.23)	0.252	——	——	2.20 (0.22-1.83)	0.405
ypT_Stage (ypT1&ypT2&ypT3 vs ypT4)	0.77 (1.53-4.23)	<0.001	2.00 (1.20-3.50)	0.012	0.77 (0.61-6.20)	0.265
ypN_Stage (ypN0 vs ypN1&ypN2)	1.20 (1.57-4.13)	<0.001	2.20 (1.30-3.60)	0.003	1.20 (1.00-8.98)	0.05
Response (CR&PR vs SD&PD)	1.30 (1.21-3.11)	0.006	1.40 (0.86-2.30)	0.180	1.30 (0.43-3.64)	0.68
Distance (≥5cm vs <5cm)	1.20 (0.60-1.67)	0.997	——	——	1.20 (0.75-6.12)	0.156

pNCT, prolonged neoadjuvant chemotherapy; TNT, total neoadjuvant therapy; CRM, circumference resection margin; EMVI, extramural vascular invasion; MMR, mismatch repair; ypT, Pathological T stage after neoadjuvant therapy; ypN, Pathological N stage after neoadjuvant therapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.